Clinical trials · Houston, TX
Locally Advanced or Metastatic Solid Tumors clinical trials in Houston
We’re tracking 478 recruiting locally advanced or metastatic solid tumors studies with a site in or near Houston — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near Houston
- NCT07359820RecruitingPhase 2
Lirafugratinib for solid tumors with FGFR2 fusion
This trial tests a targeted drug called lirafugratinib for people with advanced solid tumors (not bile duct cancer) that have a specific FGFR2 gene change. The drug blocks the faulty protein from helping the cancer grow.
Houston, TexasAges 18 years+ - NCT05673928RecruitingPhase 2
Tucatinib and T-DM1 for HER2-positive brain-metastasis tumors
This Phase 2 study tests tucatinib plus T-DM1 (ado-trastuzumab emtansine) in people with HER2-positive metastatic solid tumors that have spread to the brain. It aims to shrink brain and body tumors and help control cancer that is progressing in the brain.
Houston, TexasAges 18 years+ - NCT07213791RecruitingPhase 1
Study of a new drug for FAP-positive cancers
This trial tests a new drug (LY4337713) for cancers that have a specific protein called FAP on their surface. It may be an option for people whose cancer has continued to grow after standard treatments.
Houston, TexasAges 18 years+ - NCT07436728RecruitingPhase 1/Phase 2
Study of TAK-505 for adults with solid tumors
This trial tests TAK-505, an experimental drug, for people with advanced solid tumors including lung, colorectal, stomach, or head and neck cancers. It aims to see if the drug can help when standard treatments are no longer working or aren't suitable.
Houston, TexasAges 18 years+ - NCT06874335RecruitingPhase 1
A study of BHV-1530 for advanced solid tumors
This trial tests a new drug, BHV-1530, either alone or with another drug called cemiplimab, for people with certain advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it's safe and effective.
Houston, TexasAges 18 years+ - NCT05267626RecruitingPhase 1/Phase 2
AU-007 antibody for hard-to-remove or spread skin and lung cancers
This trial tests AU-007, an antibody that targets the IL-2 pathway, in people with certain advanced skin (melanoma) or lung (NSCLC) cancers. It’s designed for cancers that have already progressed after prior immune and other treatments, to see if AU-007 can shrink tumors or control disease.
Houston, TexasAges 18 years+ - NCT06409065Recruiting
Emotional and spiritual support for advanced cancer and caregivers
This study offers a program to help people with advanced cancer and their caregivers cope with emotional and spiritual distress. It involves talking with a counselor together to improve your well-being.
Houston, TexasAges 18 years+ - NCT07085767RecruitingPhase 3
Palazestrant and ribociclib for first-line advanced breast cancer
This trial tests a new drug (palazestrant) combined with ribociclib for people with a common type of advanced breast cancer that is estrogen receptor-positive and HER2-negative. You may qualify if you haven't had treatment for advanced disease and your cancer has either just been found or came back long after completing hormone therapy.
Houston, TexasAges 18 years+ - NCT05668962RecruitingPhase 2
Study selpercatinib plus I-131 for RET thyroid cancer that cannot take iodine
This trial tests whether combining a targeted pill (selpercatinib) with a radioactive iodine dose (I-131) can shrink thyroid cancer that has spread and no longer responds to radioactive iodine. It is for RET fusion–positive (genetically driven) thyroid cancers where the cancer cannot reliably absorb iodine anymore.
Houston, TexasAges 12 years+ - NCT07300943RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This trial tests a new drug (an ATR inhibitor) for people with advanced solid tumors that have not responded to or are not suitable for standard treatments. It aims to see if the drug is safe and effective, and it may be an option if you have good heart function and are feeling well enough to participate.
Houston, TexasAges 18 years+ - NCT06974110RecruitingPhase 1
Study of a new drug for advanced solid tumors with MSI-H or dMMR
This trial tests an oral medication called MOMA-341 in people with advanced solid tumors that have high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR). It aims to see if the drug can help when prior immunotherapy hasn't worked or isn't available.
Houston, TexasAges 18 years+ - NCT05954312RecruitingPhase 1
Study of an experimental drug for advanced solid tumors
This Phase 1 trial tests VVD-130037, a new experimental medicine, to see if it is safe and tolerable in people with advanced (metastatic or unresectable) solid cancers. If you have already tried standard treatments and your body can handle study medication, you may be eligible—especially for certain lung, head and neck, or esophageal cancer types with specific genetic changes.
Houston, TexasAges 18 years+ - NCT06562543RecruitingPhase 4
Fruquintinib for advanced colorectal cancer in minority populations
This trial tests a medication called fruquintinib (an oral pill) for people with advanced colorectal cancer that has not responded to prior treatments. It is specifically looking for participants who identify as Black or African American and/or Hispanic or Latino to help understand how the drug works in these groups.
Houston, TexasAges 18 years+ - NCT06563375RecruitingPhase 1
Testing NP-101 for advanced solid tumors
This trial tests a new drug called NP-101 for people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and see if it can shrink tumors.
Houston, TexasAges 18 years+ - NCT06782555RecruitingPhase 1/Phase 2
Study of experimental drug combo for advanced cancers
This trial tests a new combination of three drugs—evofosfamide, zalifrelimab, and balstilimab—in people with advanced prostate, pancreatic, or certain head and neck cancers that have stopped responding to standard treatments.
Houston, TexasAges 18 years+ - NCT05981703RecruitingPhase 1
Study of a new drug for advanced solid tumors
This study tests a new drug (BGB-26808) alone or with another drug (tislelizumab) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
Houston, TexasAges 18 years+ - NCT07123103RecruitingPhase 1
Study of XB371 for advanced solid tumors
This trial tests a new drug called XB371 for people with advanced solid tumors that have come back or spread. It aims to see if the drug is safe and works against the cancer.
Houston, TexasAges 18 years+ - NCT07172919RecruitingPhase 2
Continued treatment with sotorasib for KRAS G12C cancer
This study is for people who are already taking the targeted therapy sotorasib (with or without another drug called panitumumab) in an Amgen clinical trial and are still doing well. It lets you keep receiving the same treatment after your original study ends, so you don't have to stop a medicine that is working for you.
Houston, TexasAges 18 years+ - NCT06413680RecruitingPhase 1/Phase 2
Study of REGN10597 with or without cemiplimab for advanced solid tumors
This study tests a new drug called REGN10597, either alone or with cemiplimab, for people with advanced solid tumors (like melanoma or kidney cancer) that have not responded to standard treatments. The goal is to see if the combination can shrink tumors or slow their growth.
Houston, TexasAges 18 years+ - NCT06343402RecruitingPhase 1
Study of BBO-8520 for advanced KRAS G12C lung cancer
This trial tests a new oral medication called BBO-8520 for advanced lung cancer with a specific gene change (KRAS G12C mutation). It aims to see if the drug is safe and effective, and may be combined with another drug (pembrolizumab) in some groups.
Houston, TexasAges 18 years+ - NCT06907615RecruitingPhase 2
Study of HLX43 for advanced non-small cell lung cancer
This trial tests a new drug, HLX43, for people with advanced non-small cell lung cancer that has not responded to standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
Houston, TexasAges 18 years+ - NCT06581432RecruitingPhase 2
Zongertinib for advanced cancers with HER2 changes
This trial tests an experimental drug (zongertinib) for people with advanced solid tumors that have certain changes in the HER2 gene. It's for those who have already tried at least one standard treatment and need more options.
Houston, TexasAges 18 years+ - NCT06858735RecruitingPhase 2
HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma
Phase 2 trial evaluating systemic therapy ± liver-directed RT for advanced intrahepatic cholangiocarcinoma, with broad eligibility for patients who have received at least 4 cycles of gem/cis/durvalumab.
Houston, TexasAges 18 years+ - NCT05873686RecruitingPhase 1
Study of NXP900 for advanced solid tumors
This trial tests a new drug called NXP900 for people with advanced solid tumors that have not responded to other treatments. The study has two parts: one for any advanced solid tumor and another for tumors with specific genetic changes.
Houston, TexasAges 18 years+
Hear when a new Locally Advanced or Metastatic Solid Tumors trial opens near Houston, TX
We’ll email you when one opens near Houston, TX — at most once a week, no account needed, unsubscribe anytime.
Locally Advanced or Metastatic Solid Tumors trials in other cities
Where these studies are running near Houston
Institutions with a site for the recruiting locally advanced or metastatic solid tumors studies listed above.
- The University of Texas MD Anderson Cancer Center · 17 studies
- Baylor College of Medicine · 3 studies
- Oncology Consultants · 2 studies
- BRCR Global
- Clinical Trial Site
- Exelixis Clinical Site
- Investigative Site
- NEXT Oncology
What taking part in a locally advanced or metastatic solid tumors study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting locally advanced or metastatic solid tumors studies in Texas.
Common questions
- Are there locally advanced or metastatic solid tumors clinical trials near Houston?
- Yes. We're currently tracking 478 recruiting locally advanced or metastatic solid tumors studies with a site near Houston, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a locally advanced or metastatic solid tumors study near Houston?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Houston to take part?
- Not necessarily. These studies have a site near Houston, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a locally advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New locally advanced or metastatic solid tumors studies open near Houston regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.